Incyte Corporation INCY reported second-quarter 2025 adjusted earnings of $1.57 per share, which beat the Zacks Consensus ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise ...

Jejurikar, who joined P&G as an assistant brand manager in 1989, will replace Jon Moeller as part of a top leadership ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Novartis moves to block cancer drug generic in US ...